Proactive Investors - Run By Investors For Investors

Breakfast News - AIM Breakfast:Blancco Technology Group,Clinigen Group PLC,Countryliner Group Ltd,Collagen Solutions PLC,Horizonte Minerals Plc,Imaginatik Plc,MaxCyte,Omega Diagnostics Group Plc,OptiBiotix Health plc,Trinity Exploration & Production PLC

Breakfast News - AIM Breakfast:Blancco Technology Group,Clinigen Group PLC,Countryliner Group Ltd,Collagen Solutions PLC,Horizonte Minerals Plc,Imaginatik Plc,MaxCyte,Omega Diagnostics Group Plc,OptiBiotix Health plc,Trinity Exploration & Production PLC

What’s cooking in the IPO kitchen?

ADES International — Provider of offshore and onshore oil and gas drilling and production services in the Middle East and Africa, seeking raise up to $170m plus vendor sale under a Standard Listing of the Main Market. Admission due May 2017. 

Global Ports Holding — Intention to float on Standard List of the Main Market.  International cruise ports operator. Seeking $250m raise including $75m primary offer.

Dorcaster — Schedule One Update. Admission now expected on AIM 3 May. RTO of Escape Hunt raising £14m at 135p.

Verditek — Intention to float on AIM. On Admission, the Company's subsidiaries will be involved in advanced solar photovoltaic, filtration and absorption technologies specialising in providing environmental services. Raising £3.5m. Admission in May.

ADES International Holding — Intends to join the Standard List of the Main Market in May raising up to $170m plus a vendor sale. Provider of offshore and onshore oil and gas drilling and production services in the Middle East and Africa. Admission expected in May. 

Tufton Oceanic Assets – Offer extended to 9 May on specialist funds segment of  Main Market to enable investors to complete further due diligence. 

 

Breakfast buffet

MaxCyte (LON:MXCT) 277.5p £141m

The US-based global Company dedicated to driving the acceleration of discovery, development, m a n u f a c t u r i n g a n d commercialisation of nextgeneration, cell-based medicines, announced today it will present positive preclinical study results at the American Society of Gene and Cell Therapy A n n u a l Meeting (ASGCT).   The new in vitro data demonstrate the potential of MaxCyte's cGMP-compliant proprietary delivery platform to enable CRISPR gene editing in the treatment of sickle cell disease (SCD).  The work demonstrated successful CRISPR-induced corrections of the mutation behind SCD in more than 30 percent of patient-derived B cells. 

Clinigen Group (LON:CLIN) 813p £935.72m

Clinigen’s Idis Managed Access  division and Onxeo S.A have agreed to launch a M a n a g e d A c c e s s programme for belinostat (Beleodaq®) in Europe. Belinostat is for use in patients with relapsed or refractory peripheral Tcell lymphoma (PTCL).  Belinostat is a histone deacetylase inhibitor used to treat refractory or relapsed PTCL. The product received accelerated approval by the US Food and Drug Administration (FDA' in July 2014 due to the unmet medical need in this rare disease. There are no approved treatments for PTCL in Europe.  "There is a huge unmet need for patients with aggressive blood cancers such as PTCL. As the trusted global leader in access to unlicensed medicines, Clinigen is working in partnership with Onxeo to help patients gain access to this important medicine.” FYJun17 rev £302m and PBT of £49.2m.

Collagen Solutions (LON:COS) 5p £16.2m

The d e ve l o pe r a n d manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announced preliminary revenue, including other income, of £4.1m for the year ending 31 March 2017 of which approximately £3.95m was trading revenue, representing 26% growth.  This growth has been driven by an increase in the number of customers, higher volumes from key customers and an increase in new development agreements. In particular, the Company has seen its pericardium tissue business grow by 30% resulting in a specific initiative to diversify and increase its tissue supply base in Australia and New Zealand to meet the additional demand. FY2018E rev £5.4m and $1.7m pre-tax loss. 

Omega Diagnostics (LON:ODX) 23.62p £25.69m

The medical diagnostics Company focused on allergy, food intolerance and i n f e c t i o u s d i s e a s e , announces that results for the year to 31 March 2017 will be in line with market expectations. Revenues for the year are expected to be £14.3m (+3% in constant currencies and 12% on a reported basis)  and adjusted profit before tax is expected to be £1.1m. “We have reached a significant milestone in achieving design freeze with our VISITECT® CD4 development programme. We remain confident in completing the verification and validation programme to deliver a unique product which we believe will meet a large unmet medical need for people living with HIV infections in resource-limited countries.” FYMar18E rev £15m and PBT of £1.28m.

Horizonte Minerals (LON:HZM) 2.65p £31.1m

The nickel development Company focused in Brazil, announced the award of three new mineral exploration concession areas adjacent to the Araguaia North deposits forming part of Horizonte's 100% owned Araguaia nickel project which is being developed as the next major nickel project in Brazil. Three new concessions awarded, totalling 1,748 ha, are located in prospective locations containing ultramafic intrusion of a similar type to those hosting the high-grade nickel resource at Araguaia's Vale dos Sonhos deposit. Further applications totalling an area of 6,186 hectares have also been filed. Feasibility Study is progressing on schedule and on budget for delivery by the end of 2017.

Optibiotix Health (LON:OPTI) 72.5p £56.94m

FYNov16 results from  the   life sciences business developing compounds to tackle obesity, high cholesterol and diabetes. Revenue of £288k. From £28k. Losses stable at £1.5m. Cash of £3.1m. Period highlights include commercial agreements with KSF (Slimfast) and Royal DSM. Post period highlights include admission of majority o w n e d SkinBioTherapeutics to AIM and European manufacturing, supply and profit sharing agreement with Sacco S.r.l.  “We hope to build on this early success with the launch of our LPLDL® cholesterol reducing product in May of this year .”

Redstone Connect (LON:REDS) 1.92p £26.32m

FYJan17 results from the  provider of technology and services for smart buildings and commercial spaces. Revenue up 3.5% to £41.5m. Gross profit up 33% to £9.2m. Profit after tax of £2.1m (2016: loss of £2.2m). Cash of £3.2m (2016: £1.0m) and net cash of £0.8m (2016: £1.0mn). “With the successful programme of software product development achieved during the year, the Group now has an enhanced offering and is well positioned to achieve further growth.  We are focusing our investment on building sales capabilities, enabling the business to rapidly scale and to fully capitalise on the market opportunity by becoming a leader in the supply of smart b u i l d i n g solutions.”  FYJan18E rev $49.7m, PBT £2.3m. 

Imaginatik (LON:IMTK) 2.25p £3.42m

FYMar17 trading update from the innovation Company. The Company expects to report an adjusted loss after tax of £0.55m, broadly in line with market expectations. The result is stated net of an exceptional foreign exchange loss of £0.23m. Revenues flat at £3.9m. 76% renewal rate. Good progress on customer wins. 9 of 15 on multi year contracts. Several partnerships entered in H2. The directors continue to carefully monitor the Company's cash position and to consider the options available. FY Mar17E £4.2m rev and £0.5m pre-tax loss.

Trinity Exploration (LON:TRIN) 15.5p £43.77m

Q1 update from the exploration and production company focussed on Trinidad and Tobago. Average production 2,542 bopd from 2,896.  Average prices $39.4/bbl from $45.4. Cash of $13m following fundraising in January and creditor settlements.  12 well recompletions planned for 2017. Potential to increase production to 3,000 bopd. FYDec17E revenue £38.7m and pre-tax profit of £2.43m. 

Blancco Technology Group (LON:BLTG) 216p £125.7m

Q3 update. Group sales in the period were up 48% year-on-year on a constant currency basis, comprising 36% growth in erasure and 189% pro forma growth in diagnostics.  In the first nine months of the year, Group sales increased 34% year-on-year in constant currencies, with erasure growth now at 26% and pro forma diagnostics growth at 137%.  The outlook for full year 2017 sales and adjusted operating profit remains in line with market expectations. The Company has revised its projection for group net debt to around £5.5m at June year e n d a n d r e q u i r e s additional funding of a minimum of £4m over the coming weeks to address the working capital position and increase headroom. Initiating discussions with bankers and shareholders. FYDec17E rev £31.87m. PBT £7.27m. Div 2.13p.

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.

Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, does not constitute “independent investment research” for the purposes of the Financial Conduct Authority rules. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, directors, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the UK, this document is directed at and is for distribution only to persons who (i) fall within Article 19(5) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties (as those terms are defined in the rules of the Financial Conduct Authority) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by persons who would be classified as Retail Clients (as defined by the rules of the Financial Conduct Authority).

Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, directors, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

Neither the whole nor any part of this document may be duplicated in any form or by any means. Neither should this document, or any part thereof, be redistributed or disclosed to anyone without the prior consent of Hybridan LLP.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use